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ABSTRACT 
 Diabetes mellitus is the 7th leading cause of death in the United States, comprising about 
10% of the population. With intermittent fasting gaining popularity in the media as a method to 
lose weight and control chronic illness, patients with diabetes would likely turn to any of the 
fasting methods in order to better manage their disease. However, there is a paucity of 
information to support whether intermittent fasting is an effective method to control diabetes, in 
conjunction with lifestyle modifications and anti-diabetic pharmacotherapy. This review sought 
to identify clinically relevant human studies that provide evidence that intermittent fasting is 
beneficial for those who suffer from type 1 or type 2 diabetes. A systematic review of the 
published literature was performed using PRISMA protocol in order to identify clinical trials that 
evaluated the effects of fasting in patients with type 1 or type 2 diabetes, specifically focusing on 
body weight (kg), hemoglobin A1C (%), and blood plasma glucose levels (mmol/L). Four 
randomized controlled trials and one case report of fasting in adults on anti-diabetic therapy with 
diabetes were identified. Improvements in weight, A1C, and/or fasting plasma glucose were 
identified in all of the studies. Patients may approach their health care providers with the desire 
to utilize fasting as an alternative to effectively manage their diabetes. Providers can use the 
studies included in this review as well as others that are available as a guide in order to make 
proper recommendations and monitor their patients safely. However, more studies should be 
performed in order to make accurate claims regarding the long-term effects of intermittent 
fasting among patients with diabetes. 
KEYWORDS: diabetes mellitus, intermittent fasting, alternate-day fasting, intermittent energy 
restriction, time-restricted feeding, intermittent dieting, periodic fasting 
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INTRODUCTION 
 Fasting, an ancient practice, has recently gained popularity in mainstream media as a 
means to lose weight and control chronic illness1, 2. Diabetes mellitus, affecting about 10% of the 
US population, is a chronic condition characterized by hyperglycemia due to insulin resistance or 
deficiency3. Diabetes may require intensive lifestyle modifications and/or pharmacological 
management, resulting in long-term end-organ damage if left untreated3. Any of the intermittent 
fasting (IF) regimens may seem attractive to patients with either type 1 or type 2 diabetes if 
typical anti-diabetic therapies become too costly, cause adverse effects, or fail. 
IF describes eating patterns that cycle between feeding and fasting periods that specify 
when to eat, rather than what to eat, with the end goal of caloric restriction1, 2. Common IF eating 
patterns include time-restricting feeding, in which energy intake is restricted for consecutive 
hours in a day, alternate-day fasting, in which energy intake is restricted every other day, and 
modified fasting, in which energy intake is restricted to any two or three days of the week1,3. 
Peer-reviewed human IF studies are limited while a majority of the information is written 
by health gurus or is based on rat studies1. Several studies show that IF is effective for weight 
loss in overweight and obese adults4-7. Trial data on fasting patients with diabetes is scarce. A 
12-week randomized control trial by Varady et al (2013) demonstrated a 6% decrease in fasting 
glucose levels in the alternate-day fasting group compared to the control group with no 
restrictions8. Another randomized control trial by Klempel et al (2012) showed reductions in 
glucose and insulin levels (P<0.05) in an 8-week IF study6. Both studies had subjects with 
varying body mass indices (BMI 20-39.9 kg/m2) who were non-diabetic. These results show 
promise for the use of therapeutic fasting, but more studies should be performed in patients with 
diabetes to fully understand IF as a diet strategy.  
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 The objective of this systematic review is to utilize the limited data to provide 
recommendations on how to safely monitor patients with diabetes who want to try IF. Religious 
fasting regimens and animal studies will not be included. 
METHODS 
Database Search Strategy 
 A systematic review of the literature was performed using electronic databases for 
published, peer-review articles in English. Major databases that were used in this review were      
PubMed, Science Direct, CINAHL Plus, and Cochrane Collection Plus. Searches were 
performed using keywords “diabetes mellitus” in combination with either “intermittent fasting,” 
“alternate-day fasting,” “intermittent energy restriction,” “time-restricted feeding,” “intermittent 
dieting,” or “periodic fasting.” Reference lists of selected articles were also inspected due to the 
limited number of articles that resulted during the search. Titles of studies were critiqued by 
looking for any keyword combination. Of those selected, the “Methods” sections were screened 
using the inclusion and exclusion criteria (see section on “Inclusion and Exclusion Criteria”). 
The Preferred Reporting Items of Systematic Reviews and Meta-Analyses (PRISMA) protocol 
was used in order to determine which studies were eligible to be included in the review. 
Protocol Used 
 PRISMA, composed of a flowchart and a checklist, is an organized method to improve 
the reporting quality of the papers included in this review9. The flowchart assists with the 
identification, screening, eligibility, and inclusion process for papers being reviewed. The 27-
item checklist pertains to the quality of the content of a systematic review or meta-analysis, 
including the title, abstract, methods, results, discussion, and funding. A total of 376 records 
were identified through electronic database searches. The studies were compiled in a list and 
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arranged in alphabetical order of the primary author. 79 duplicate studies were then removed by 
manually reviewing the list. 297 records were left to be screened for relevancy of the title and 
abstract (see “Inclusion and Exclusion Criteria” below). Of those, 267 papers were excluded due 
to irrelevancy, leaving 30 full-text articles to be assessed for eligibility. 25 of those studies were 
excluded for not meeting inclusion criteria, with a total of 5 studies included in the qualitative 
synthesis. 
Inclusion and Exclusion Criteria 
 The inclusion and exclusion criteria across the final papers that were selected had several 
similarities. Inclusion criteria included adults over the age of 18 with type 1 or type 2 diabetes on 
anti-diabetic therapy with an A1C > 6.5%. Exclusion criteria included animal studies, religious 
fasting, pregnant and/or lactating subjects, and those with previous weight loss surgery. Studies 
in which fasting glucose results were unavailable were not excluded due to the paucity of data.  
Setting and Subjects  
 In both the 2016 and 2018 Carter et al studies, the participants were recruited to the 
University of South Australia from the general population with the use of public 
advertisements10,11. There were no differences of inclusion criteria between the two trials. 
Participants from the Corley et al (2018) study were recruited from secondary care diabetes 
clinics, local community networks, and primary care practices around New Zealand and then 
attended the Centre for Endocrine, Diabetes, and Obesity Research at Wellington Hospital12. In 
the Furmli et al (2018) study, a chart review took place in the Intensive Dietary Management 
Clinic in Toronto, Canada, and was performed with the three case study patients who provided 
verbal and written consent to participate13. Lastly, the subjects in the Overland et al (2017) study 
were eligible to participate if they were adults with type 1 diabetes with a BMI of 25-40 who 
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attended the Diabetes Centre at Royal Prince Alfred Hospital in Sydney, Australia14. Each study 
obtained approval from their own respective ethics committees and all subjects were provided 
informed written consent to proceed with the experiments. 
RESULTS  
Characteristics of subjects 
 Each study featured adult, overweight or obese subjects with preexisting type 1 or 2 
diabetes that were being treated with anti-diabetic agents. Each study except one showed that the 
subjects had a starting BMI of >25 and a baseline A1C of >6.5%. The three case subjects in 
Furmli et al (2018) did not disclose their heights so BMI could not be obtained; however, initial 
waist circumference ranged from 89-123 cm and weight ranged from 61-97.1 kg13. Each of the 
subjects in the Furmli study also had comorbidities which included hyperlipidemia, 
hypertension, chronic kidney disease, and renal cell carcinoma13. Subjects in the other four 
studies did not have any diabetes-related organ damage or comorbidities other than overweight 
or obesity10-12,14. 
Recruitment/response 
 All five of the studies included in this review revealed similar findings, in that IF is 
associated with significant decreases in body weight, A1C, and fasting plasma glucose levels 
(Table 1). Decreases in body weight ranged from 3.3-13.3%10-14. In addition, all studies showed 
significant improvement in A1C levels, with Corley et al (2018) showing the largest decreases  
(-7.1% for the consecutive fasting group and -8.5% for the non-consecutive fasting group)12. 
Corley et al (2018) also showed that IF was associated with a lower-than-expected and clinically 
acceptable risk of hypoglycemia, when combined with weekly supervision, hypoglycemia 
education, and medication reduction at baseline12. The most notable outcome in Furmli et al 
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(2018) is that all subjects discontinued their insulin use completely13. Fasting glucose results 
were only available in two studies, both showing significant decreases11,12. Improvements in 
quality of life and enjoyment of the active participation in their diabetes management via fasting 
was also noted by subjects12,13. 
 
Table 1. Changes in body weight, A1C, and fasting glucose levels from baseline to end of studies. 
Study Type N Subjects Treatment/Control Body 
Weight 
A1C Fasting 
Glucose 
Carter et al 
(2016)10 
Pragmatic pilot 
randomized trial 
63 Adults; diagnosed with T2DM, 
on anti-diabetic medication 
BMI > 27 
Avg A1C 7.3% 
Moderate continuous energy 
restriction 
-5.9% -0.7% 
 
-- 
2-day severe energy restriction w/ 5 
days of habitual eating 
-5.9% -0.7% -- 
Carter et al 
(2018)11 
Randomized 
non-inferiority 
pilot study 
97 Adults; diagnosed with T2DM, 
on anti-diabetic medication 
BMI > 27 
Avg A1C 7.3%  
Continuous energy restriction diet -5.0% -0.5% -11.8% 
Intermittent energy restriction diet -6.8% -0.3% -11.8% 
Corley et al 
(2018)12 
Randomized 
control trial 
37 Adults; diagnosed with T2DM, 
on anti-diabetic medication 
BMI 30-45 
Avg A1C 6.7-10%  
Consecutive fast 2d/wk -2.9% -7.1% -15.9% 
Non-consecutive fast 2d/wk -3.3% -8.5% -12.2% 
Furmli et al 
(2018)13 
Case report 3 Adults; diagnosed with T2DM, 
on anti-diabetic medication 
Initial waist circumference: 89-
123 cm 
Initial weight: 61-97.1 kg 
Alternating 24hr-fast 3d/wk 
 
-13.3% -0.2% -- 
Overland et 
al (2017)14 
Randomized 
parallel group 
pilot study 
10 Adults; diagnosed with T1DM, 
on insulin 
BMI 25-40 
Avg A1C 6.5-10%  
Continuous moderate energy 
restriction: -30% relative to weight 
maintenance energy needs  
-3.9% -0.1% -- 
Severe energy restriction: 2d/wk -7.0% -0.0% -- 
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DISCUSSION 
Main Findings 
 These studies show that when individuals with type 1 or type 2 diabetes on anti-diabetic 
medications incorporate IF into their lifestyle, statistically significant decreases in body weight, 
A1C, and fasting blood glucose occur (see Table 1). When comparing intermittent energy 
restriction to continuous energy restriction, as in Carter et al (2016 and 2018) and Overland et al 
(2017), decreases in body weight and A1C are similar10,11,14. This suggests that any of the IF 
regimens could serve as a viable option for losing weight and lowering blood sugar levels. IF 
may increase patient adherence since the primary focus is when to eat, as opposed to continuous 
energy restriction, or caloric restriction, which limits the amount of calories eaten each day. In 
the Corley et al (2018) study, there were no differences in the results between the consecutive 
and the non-consecutive 2-day per week fast12. This suggests that a patient may fast everyday or 
every other day and achieve the same results, depending on preference.  
Comparison of Findings with those Reported in the Literature 
 A systematic review by Horne, Muhlestein, and Anderson15 showed that fasting was 
associated with improvements in weight and other cardiovascular and metabolic parameters, 
such as triglycerides, LDL-cholesterol particle size, and C-reactive protein. Patient populations 
of each study varied including individuals who were healthy, obese, elderly, or had a diagnosis 
of coronary artery disease or diabetes. Improved mood was also reported in two randomized 
control trials. The overall results of the review seem promising in decreasing the risk of 
cardiovascular disease, diabetes, and mental health conditions, but further studies need to be 
performed on a larger scale to make more accurate claims.   
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Strengths and Limitations 
 A limitation of this study is the scarcity of published literature regarding IF and its effects 
in persons with diabetes. The fact that all of the studies identified in this review were published 
within the last 4 years indicates this is an area of active interest and ongoing research. While 
current, these studies are limited to populations in Australia, New Zealand, and Canada and may 
not be generalizable. Another limitation is differences in the length of treatment for each study, 
ranging from 12 weeks to 12 months. In addition, Furmli et al (2018) and Overland et al (2017) 
had the smallest sample sizes, undermining the external validity of this review. Furthermore, 
only one study involved subjects with type 1 diabetes while the other four studies had subjects 
with type 2 diabetes. 
Implications for Research 
 Future studies should take place in other countries for longer durations with larger sample 
sizes. Collectively, these factors would help the data to be more generalizable and allow 
clinicians to make more comprehensive recommendations for long-term fasting. More patients 
with type 1 diabetes should be included so that proper guidelines can be made with regards to 
fasting, insulin use, and the risk for hypoglycemia. 
Implications for Clinical Practice 
     Educating patients on the benefits of IF may help control diabetes and wean the use of oral or 
injectable anti-diabetic agents. Fasting might be appealing to patients who are averse to taking 
medication and wish to avoid side effects. Medications can also be very costly, and IF is an 
inexpensive intervention that can be done in a variety of ways, allowing patients to choose how 
they fast based on personal preference. Since IF is a popular diet, providers need to know the 
risks and the benefits before counseling and managing patients.  
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In order for health care providers to optimally monitor patients with diabetes during 
fasting, they should seek guidance from peer-reviewed articles. The American Diabetes 
Association (ADA) does not have specific recommendations for patients with diabetes who want 
to try IF. However, an article written by Al-Arouj et al (2010) released by the ADA provides 
recommendations for religious fasting among patients with diabetes16. To avoid the risk of 
hypoglycemia, the article stresses the importance of individualized treatment plans, frequent 
blood glucose checks, and proper exercise and nutrition. Al-Arouj et al makes specific 
recommendations regarding medication adjustments, depending on the type of anti-diabetic 
medication the patient is taking16. Providers can use this article as a starting guide, as well as 
another article by Grajower & Horne, which makes similar recommendations regarding 
medication adjustments, but specifically for various IF regimens1.  
 With proper counseling and monitoring by health care providers, patients with diabetes 
can live longer, healthier, and happier lives through fasting. Though these results seem 
reassuring, future studies should be performed in order to provide proper recommendations 
regarding the long-term effects of IF among patients with diabetes. 
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